| HOME >> MEDICINE >> TECHNOLOGY |
Table 3.35: Clinical Application of Quantitative HBV DNA Testing 91
Table 3.36: Lower Detection Limits of HBV DNA Assays 93
Table 3.37: Summary of Molecular Diagnostic Assays for Testing HBV 95
Table 3.38: Global Market for HBV Diagnostic Testing, 2000-2010 95
Table 3.39: U.S. Market for HBV Diagnostic Testing, 2000-2010 95
Table 3.40: Global Market Forecast for HBV Diagnostic Testing, 2011-2016 96
Table 3.41: U.S. Market Forecast for HBV Diagnostic Testing, 2011-2016 96
Table 3.42: HBV Molecular Diagnostics Market: Market Drivers Ranked in Order of
Impact 96
Table 3.43: HBV Molecular Diagnostics Market: Market Restraints Ranked in Order
of Impact 97
Table 3.44: Hepatitis B Facts 98
Table 3.45: U.S. HCV Statistics 104
Table 3.46: Worldwide Rate of HCV Cases 104
Table 3.47: Efficiency of Available HCV Screening Tests 106
Table 3.48: Commercially Available Molecular Diagnostic Products for HCV Assay
112
Table 3.49: Global Market for DNA HCV Diagnostic Testing, 2005-2010 112
Table 3.50: U.S. Market for DNA HCV Diagnostic Testing, 2005-2010 112
Table 3.51: Global Market Forecast for NAT HCV Diagnostic Testing, 2011-2016 113
Table 3.52: U.S. Market Forecast for NAT HCV Diagnostic Testing, 2011-2016 113
Table 3.53: Major Companies Marketing HCV Molecular Diagnostic Tests: Market
Size and Share, 2010 113
Table 3.54: HCV Molecular Diagnostics Market: Market Drivers Ranked in Order of
Impact 114
Table 3.55: HCV Molecular Diagnostics Market: Market Restraints Ranked in Order
of Impact 115
Table 3.56: Recommendations for HCV Diagnostic Testing 117
Table 3.57: Number of Pap Smears Performed by Country, 2009 118
Table 3.58: Qiagen's Digene HC2 High-risk HPV DNA Test 122
Table 3.59: Commercially Available Molecular Diagnostic Products for HPV Assay
128<
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |